Propylparaben Exposure During Pregnancy Raise the Risk of Breast Cancer by Angela Mohan on March 16, 2021 at 6:36 PM
Exposure to low doses of propylparaben an estrogen-like chemical used as a preservative in personal care products and foods, can modify pregnancy-related changes in the breast in ways that may reduce the normal protection against breast cancer that pregnancy hormones convey, according to a new study being published in the Endocrine Society s journal
Endocrinology.
These results, from an animal study that also will be presented at ENDO 2021, the Endocrine Society s annual meeting, lend evidence that propylparaben is an endocrine-disrupting chemical, the researchers say.
An endocrine-disrupting chemical interferes with the actions of hormones in the body. These chemicals can affect hormone-sensitive organs such as the mammary gland, the milk-producing duct in the breast, said the study s senior author Laura N. Vandenberg of the University of
Vanguard News
Niola foundation celebrates World Colorectal Cancer Day
On
Oluwatunmise Mafe
In commemoration of Colorectal Cancer month, Niola Cancer Care Foundation in collaboration with Olufunke Kikelomo Olugbemi Cancer foundation held its first symposium on Saturday, March 6th 2021.
Colorectal cancer is a cancer of the colon or rectum, located at the digestive tract’s lower end. Some symptoms include changes in bowel habits, changes in stool consistency, blood in the stool, abdominal discomfort, fatigue and weight loss.
Some causes may be due to Genetics; History of Colorectal Cancer in the family; Lifestyle; eating habits, drinking, smoking, General; Age, Obesity, Type II Diabetes, Past records of inflammatory Bowel disease.
Artificial Intelligence (AI) in Breast Cancer Screening by Colleen Fleiss on February 26, 2021 at 11:06 PM
Google health division explores whether Artificial Intelligence (AI) models can help reduce the time to breast cancer diagnosis, narrowing the assessment gap and improving the patient experience.
Women who choose to take part in the study may have their mammograms reviewed by an investigational AI model that flags scans for immediate review by a radiologist if they show a higher likelihood of breast cancer, Google Health said in a blog post on Thursday.
If a radiologist determines that further imaging is required, the woman will have the option to undergo this imaging on the same day.
Scientists Develop Model That Simulates Breast Cancer by Angela Mohan on February 23, 2021 at 12:17 PM
Scientists developed new xenograft model that simulates breast cancer. The team, led by EPFL researcher George Sflomos, at the laboratory of Professor Cathrin Brisken grafted two ILC-derived metastatic breast cancer cell lines and freshly resected ILC tumors from patients directly into the milk ducts of mice which are immune deficient. The study is published in
EMBO Molecular Medicine.
Invasive lobular carcinoma (ILC) is a type of breast cancer that begins in the milk-producing glands (lobules) of the breast. It covers 10-15% of all breast cancer cases, has a high risk of late recurrence, unique metastatic sites, high sensitivity to hormones, unpredictable responses to therapies, unique histopathology, distinctive biology, and resists chemotherapy.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Therapeutic Solutions International Appoints Internationally Renowned Tumor Immunologist Dr. Boris Minev to its Scientific Advisory Board
February 16, 2021 GMT
ELK CITY, Idaho, Feb. 16, 2021 /PRNewswire/ Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today appointment of Dr. Boris Minev to the Scientific Advisory Board of the Company. Dr. Minev joins other internationally renowned tumor immunologists including Dr. Francesco Marincola, Dr. Santosh Kesari, and Dr. Feng Lin.
Dr. Boris Minev is currently the President of Medical and Scientific Affairs at Calidi Biotherapeutics, Inc. in San Diego, CA. Dr. Minev has a stellar track record of successes in the area of cancer immunotherapy, being a developer of Melacine® the first tumor vaccine to obtain regulatory approval. He held a position as the Director of Immunotherapy and Translational Oncology at Genelux Corpo